Search

Displaying results 1701 - 1710 of 7673 in total
  1. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … [A39986] Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease

  2. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.

  3. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.

  4. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.

  5. Drug

    Ziconotide

    go.drugbank.com/drugs/DB06283
    ApprovedInvestigational

    [L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be

  6. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.

  7. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.

  8. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists. … This would produce an effect similar to the amphetamine/barbiturate combinations previously used in psychiatric medications.

  9. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular … Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct

  10. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.